Background/Aims: Dexamethasone (Dex) induces injuries to human osteoblasts. In this study, we tested the potential role of the long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (Lnc-MALAT1) in this process. Materials: Two established human osteoblastic cell lines (OB-6 and hFOB1.19) and primary human osteoblasts were treated with Dex. Lnc-MALAT1 expression was analyzed by quantitative real-time polymerase chain reaction assay. Cell viability, apoptosis, and death were tested by the MTT assay, histone-DNA assay, and trypan blue staining assay, respectively. AMP-activated protein kinase (AMPK) signaling was evaluated by western blotting and AMPK activity assay. Results: Lnc-MALAT1 expression was downregulated by Dex treatment in the established osteoblastic cell lines (OB-6 and hFOB1.19) and primary human osteoblasts. The level of Lnc-MALAT1 was decreased in the necrotic femoral head tissues of Dex-administered patients. In osteoblastic cells and primary human osteoblasts, forced overexpression of Lnc-MALAT1 using a lentiviral vector (LV-MALAT1) inhibited Dex-induced cell viability reduction, cell death, and apoptosis. Conversely, transfection with Lnc-MALAT1 small interfering RNA aggravated Dex-induced cytotoxicity. Transfection with LV-MALAT1 downregulated Ppm1e (protein phosphatase, Mg 2+/
Introduction
Dexamethasone (Dex) is prescribed to patients with chronic inflammatory and autoimmune diseases [1] . However, excessive or long-term Dex treatment induces cytotoxic effects in human osteoblasts, serving as a primary cause of osteoporosis and osteonecrosis [2, 3] . Dex treatment has been shown to exert direct cytotoxic effects on cultured human osteoblasts in vitro [2, [4] [5] [6] [7] . Studies focusing on the pathological mechanisms of Dex-induced injuries in osteoblasts have been previously conducted [8] [9] [10] [11] [12] [13] , and have been the main area of focus of our research group as well [4, 9, 11, 14] .
The long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) [15] , or Lnc-MALAT1, is an abundant and highly conserved lncRNA [16] [17] [18] . It was first discovered as a prognostic marker for lung cancer metastasis [19] . Lnc-MALAT1 is overexpressed in various human cancers [16] [17] [18] . It interacts with polycomb-2 to regulate histone modifications and cell proliferation [20] . Furthermore, it interacts with serine/arginine-rich proteins to regulate the subcellular localization of splicing regulatory proteins [21] . Recent studies have proposed the pro-survival function of Lnc-MALAT1 [22] . However, the potential activity of Lnc-MALAT1 in Dex-treated human osteoblasts has not yet been studied.
AMP-activated protein kinase (AMPK) coordinates the signaling of several metabolic pathways [23, 24] . It is composed of α-, β-, and γ-subunits [23, 24] . Phosphorylation of the α1-subunit at Thr-172 is essential for AMPK activation [23] [24] [25] . Activated AMPK is shown to promote cell survival under stress conditions [26] . AMPK can attenuate oxidative stress via activation of nicotinamide adenine dinucleotide phosphate (NADPH) [27] and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling [28] [29] [30] . Recent studies have implied that AMPK activation can efficiently protect human osteoblasts from Dex-induced injuries [4, 5, 30, 31] .
One strategy to induce AMPK activation is to inhibit the expression of its phosphatases [32] , which were largely unknown until recently [33] . Protein phosphatase Mg 2+/ Mn 2+ -dependent (Ppm) 1e (Ppm1e) is an important AMPKα phosphatase [33] . It belongs to the Ppm family [34, 35] . Our previous study demonstrated that microRNA-135b downregulated Ppm1e expression to activate AMPK signaling, which in turn protected osteoblastic cells from Dex-induced injuries [4] . In the present study, our results suggest that Lnc-MALAT1 protects human osteoblasts from Dex-induced injury via activation of Ppm1e-AMPK signaling.
Materials and Methods

Chemicals and reagents
Dexamethasone, puromycin, neomycin, and JC-1 fluorescent dye were purchased from Sigma-Aldrich (St. Louis, MO). Antibodies were purchased from Cell Signaling Technology (Beverly, MA) and Santa Cruz Biotechnology (Santa Cruz, CA). Fetal bovine serum, Dulbecco's modified Eagle's medium, antibiotics, and other cell culture reagents were obtained from Gibco-BRL (Grand Island, NY). The cell lysis buffer was purchased from Sigma-Aldrich (Wuxi, China). TRIzol reagent for RNA assays was obtained from Invitrogen (Shanghai, China). mRNA primers were synthesized by GenePharma Co. (Shanghai, China). The 2′,7′-dichlorofluorescein diacetate (DCF-DA) fluorescent dye for reactive oxygen species (ROS) assay was provided by Roche Diagnostics (Mannheim, Germany).
Cell culture
Established OB-6 [2] and hFOB1.19 [36] human osteoblastic cells were purchased from the Cell Bank of the Shanghai Institute of Biological Sciences (Shanghai, China). Cells were cultured as described previously [2, 36] . The primary human osteoblasts were provided by Dr. Ji [6] and cultured under previously described conditions [6, 37] . Primary osteoblasts at passage 3-10 were utilized for in vitro experiments. All protocols involving the use of human cells were approved by the Ethics Committee of Nantong University and Declaration of Helsinki.
Quantitative real-time polymerase chain reaction assay As described previously [4, 38] , TRIzol reagent was used to extract total cellular RNA, which was then reverse-transcribed. cDNA was then amplified by quantitative real-time polymerase chain reaction (qPCR). SYBR Green PCR kit (Applied Biosystems, Shanghai, China) was utilized to detect the expression of the listed mRNAs. Melting curve analysis was applied to calculate the product melting temperature. Quantification of mRNA expression was performed using the ΔΔ Ct method, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the internal control. The primer sequences used for theNrf2 genes, including heme oxygenase-1 (HO1), NAD(P)H quinone oxidoreductase 1 (NQO1), and γ-glutamyl cysteine ligase catalytic subunit (GCLC) were described previously [39] . Ppm1e mRNA primer sequences were described early [4] . Lnc-MALAT1 primer sequences were as follows: forward: 5′-AAAGCAAGGTCTCCCCACAAG-3′, reverse: 5′-GGTCTGTGCTAGATCAAAAGGCA-3′, as described previously [40] . Lnc-MALAT1 level was normalized to that of U6 mRNA.
Forced Lnc-MALAT1 expression
The Lnc-MALAT1 sequence was sub-cloned into the lenti-vector-plasmid pCDH-CMV-MCS-EF1-coGFPpuro to generate pCDH-CMV-MALAT1-EF1-coGFP-puro, which was transfected into 293T cells with the lentiviral packaging vectors, psPAX2 and pMD2.G, to produce the lentivirus LV-MALAT1. Human osteoblastic cells or primary osteoblasts were seeded onto 6-well plates at a density of 1×10 5 cells per well. Cells were infected with control virus or LV-MALAT1 for 48 h, followed by culture in puromycin (1 μg/mL)-containing medium for another 2-3 weeks. The expression of Lnc-MALAT1 in stable cells was determined by qPCR assay.
Lnc-MALAT1 small interfering RNA Small interfering RNAs (siRNAs) targeting Lnc-MALAT1,including siMALAT1-1(5′-GAAUUCCGGUGAUGCGAGU-3′) and siMALAT1-2 (5′-GGCAAUAGAGGCCCUCUAA-3′), were obtained from GenePharma Co. Human osteoblastic cells or primary osteoblasts were seeded onto 6-well tissue culture plates at a density of 1×10 5 cells per well. Cells were transfected with 500 nM of Lnc-MALAT1 siRNA or scramble control siRNA (siR-C) by Lipofectamine 2000 (Invitrogen) for 48 h.Lnc-MALAT1 knockdown efficiency was determined by qPCR assay.
Western blotting
As described in our previous studies [9, 11] , total cell lysates were separated bydenaturing on 10% polyacrylamide gels [41] , and then transferred to polyvinylidene difluoride membranes (Millipore, Shanghai, China). The membranes were blocked with 10% non-fat dry milk, followed by incubation with specific primary and secondary antibodies. The antigen-antibody binding was detected using enhanced chemiluminescence (ECL) reagents (Pierce, Shanghai, China). ImageJ software was utilized for quantification of the total gray area of each protein band.
Cell death assay
Human osteoblastic cells or primary osteoblasts were seeded onto 12-well plates at a density of 5×10 4 cells per well. Following treatment with Dex, cells were trypsinized. Cells were stained with trypan blue, and cell counting was performed using a cytometer. The cell death percentage was then calculated using the following formula: Cell death percentage (%) = (number of trypan blue-stained cells)/(number of total cells) [11] . [9, 11] . MTT optical densities (ODs) at 550 nm were recorded.
Detection of apoptosis by enzyme-linked immunosorbent assay
Human osteoblastic cells or primary osteoblasts were seeded onto 96-well plates (3×10 3 cells per well). After the applied treatment, a histone-DNA enzyme-linked immunosorbent assay (ELISA) kit (Roche, Palo Alto, CA) was used to quantify cell apoptosis [42] . Histone-DNA ELISA OD at 450 nm was recorded.
AMPKα1 knockdown
AMPKα1 short hairpin RNA (shRNA) was used as described in our previous study [42] . Human osteoblastic cells or primary osteoblasts were seeded onto 6-well plates. The lentiviral AMPKα1 shRNA construct (10 μL virus/mL) was added directly to the cells for 24 h. Cells were cultured in puromycin (1 μg/mL)-containing medium for 2-3 weeks. Knockdown of AMPKα1 in stable cells was verified by western blotting.
AMPK dominant negative mutation
Cells were seeded onto 6-well plates at a density of 1×10
5 cells per well. The dominant negative mutant of AMPKα1 (dn-AMPKα1; T172A; Flag-tagged; provided by Dr. Lu [43] ) was transfected into cultured cells using Lipofectamine 2000 [43] . Stable cells were selected by neomycin (2 μg/mL; Sigma-Aldrich). The expression of dn-AMPKα1 was confirmed by western blotting.
AMPK activity assay
Following treatment, 500 μg of total cell lysate proteins were incubated with anti-AMPKα1 antibody (Cell Signaling Technology). As described previously, AMPK activity was measured in kinase assay buffer usingthe AMP-[γ-
32
P] ATP mixture along with the SAMS (HMRSAMSGLHLVKRR) peptide [44] . To stop the reaction, phosphocellulose paper was added. AMPK radioactivity was measured with a scintillation counter.
NADPH activity assay NADPH activity was testedby a previously described method [45] . Following treatment, intracellular NADPH and NADP + levels were examined [46] . Briefly, two million cells were plated onto 10cm dishes and lysed in 300 μL of extraction buffer after the applied treatment [27] . For NADPH extraction, 100 μL of the supernatant was incubated at 60 °C for 30 min. Next, 100 μL of NADP-cycling buffer [27] with 1.0 U glucose-6-phosphate dehydrogenase (G6PD; Sigma-Aldrich) was added. After 1 min of incubation at 30 °C, 20 μL of 10 mM glucose 6-phosphate (G6P; Sigma-Aldrich) was added to the mixture, and the change in absorbance at 570 nm was measured. The concentration of NADP + was calculated by subtracting [NADPH] from [total NADP] [27] . The relative NADPH activity was calculated by determining the NADPH/NADP + ratio.
ROS measurement
Cells were seeded onto 12-well plates at a density of 5×10 4 cells per well. Following treatment, ROS production was measured bythe DCF-DA fluorescent dye assay. Cells were incubated with 5μM of DCF-DA for 30 min. Fluorescence intensity was measured using a flow cytometer (BD Biosciences, Shanghai, China).
Mitochondrial depolarization assay
After the applied treatment, mitochondrial depolarization ("∆Ψ") was tested using the mito-dye JC-1, which aggregates to form green monomers after mitochondrial depolarization [47] . Cells were initially seeded onto 24-well tissue culture plates. The protocol for mitochondrial depolarization assayusing JC-1 has been discussed previously [48] . JC-1 fluorescence ODs were recorded at 550 nm. Human tissue collection and analysis As described previously [4] , surgery-isolated necrotic femoral head tissues and thesurrounding normal femoral head tissues were collected from patients who were taking Dex and undergoing femoral head resection. Fresh tissues were dissolved in tissue lysis buffer. The protocols were approved by the Ethics Committee of Nantong University. Written informed consent was obtained from each patient. A total of nine patients were included. All clinical investigations were conducted according to the criteria set by the Declaration of Helsinki.
Statistical analysis
All quantitative data are presented are the mean ±standard deviation (SD) from at least three samples per data point. Statistical differences between groups were determined by one-way analysis of variance followed by multiple comparisons performed using Bonferroni post-hoc test. All analyses were performed with SPSS version 18.0 statistical software (SPSS Co., Chicago, IL). Values of p< 0.05 were considered statistically significant.
Results
Lnc-MALAT1 expression is downregulated in Dex-treated human osteoblasts and in the necrotic femoral head tissues of Dex-administered patients
To test whether Dex can affect Lnc-MALAT1 expression, two established human osteoblasticcell lines, OB-6 and hFOB1.19, were treated with Dex (1 μM) [4, 5] . After 12h of incubation, Lnc-MALAT1 expression level was significantly decreased in OB-6 (Fig. 1A ) and hFOB1.19 cells (Fig. 1B) , as well as in the primary human osteoblasts (Fig. 1C) . Similarly, Lnc-MALAT1 level was also reduced in the necrotic femoral head tissues of Dex-administered patients [4] . However, its level in the paired surrounding normal femoral head tissues was relatively high (Fig. 1D) . 
Forced overexpression of Lnc-MALAT1 protects human osteoblasts from Dex-induced injuries
Lnc-MALAT1 expression was downregulated following Dex treatment in human osteoblasts, indicating its potential activity in Dex-induced cytotoxicity. Next, a lentiviral Lnc-MALAT1 expression construct (LV-MALAT1) was transfected into OB-6 cells. Following puromycin selection, two stable OB-6 cell lines were established: LV-MALAT1-L1 and LV-MALAT1-L2. By performing qPCR assay, we showed that Lnc-MALAT1 expression level was significantly increased in the stable cells transfected with LV-MALAT1, even after Dex treatment (Fig. 2A) . Additionally, Dex-induced viability reduction (MTT OD) was attenuated following LV-MALAT1 transfection in OB-6 cells (Fig. 2B) . Furthermore, results from Histone-DNA ELISA apoptosis assay and trypan blue staining assay showed that Dex-induced cell apoptosis and death were significantly inhibited in stable OB-6 cells transfected with LV-MALAT1 (Fig. 2C and D) . Treatment with LV-MALAT1 alone failed to affect OB-6 cell survival, death, or apoptosis (Fig. 2B-D) .
In hFOB1.19 osteoblastic cells, forced overexpression of Lnc-MALAT1 attenuated Dex-induced viability reduction (Fig. 2E) . In primary human osteoblasts, cells transfected with LV-MALAT1 were protected from Dex-induced injury (Fig. 2F) . Together, these results indicate that forced overexpression of Lnc-MALAT1 protects human osteoblasts from Dexinduced injury.
Lnc-MALAT1 silencing aggravates Dex-induced cytotoxicity in human osteoblasts
Next, we hypothesized that Lnc-MALAT1 silencing enhances Dex-induced cytotoxicity. To test this hypothesis, Lnc-MALAT1 siRNAs (siMALAT1-S1/S2) were transfected into OB-6 cells. As shown in Fig. 3A , each of the applied siRNA induced over 90% reduction of Lnc-MALAT1 expression in OB-6 cells. Lnc-MALAT1 siRNA induced minor but significant viability reduction (Fig. 3B), apoptosis (Fig. 3C) , and death (Fig. 3D ) in OB-6 cells. Additionally, Lnc-MALAT1 silencing aggravated Dex-induced cytotoxicity, thereby enhancing viability reduction (Fig. 3B) , cell apoptosis (Fig. 3C) , and death (Fig. 3D) . In hFOB1.19 osteoblastic cells and primary human osteoblasts, similar results were obtained. Lnc-MALAT1 siRNA transfection significantly enhanced Dex-induced viability reduction ( Fig. 3E and F) . Lnc-MALAT1 silencing alone only slightly inhibited the viability of hFOB1.19 cells and primary osteoblasts (Fig. 3E and F) . These results further support the role of Lnc-MALAT1 in Dexinduced osteoblast injury.
AMPK activation mediates LV-MALAT1-induced protection against Dex-induced cytotoxicity
Our previous study showed that activation of Ppm1e-AMPK signaling could protect human osteoblasts from Dex-induced injuries [4] . The potential effect of Lnc-MALAT1 on this signaling was tested. By performing qPCR assay, we showed that transfection with LV-MALAT1 decreasedPpm1e mRNA expression in OB-6 cells (Fig. 4A) . Ppm1e protein expression was also downregulated, causing increased phosphorylation of AMPKα1 (at Thr-172) and its major downstream protein, acetyl-coA carboxylase (ACC; at Ser-79) (Fig. 4B) . Further studies showed that AMPK activity was also increased in LV-MALAT1-expressing OB-6 cells (Fig. 4C) . These results suggestthat forced overexpression of Lnc-MALAT1 activates AMPK signaling in OB-6 cells.
Next, genetic strategies were employed to inhibit AMPK activation. As described previously [4] , OB-6 cells were treated with AMPKα1 shRNA lentivirus (sh-AMPKα1) to stably knockdown AMPKα1 (Fig. 4D) . Additionally, a dominant negative mutant of AMPKα1 (dn-AMPKα1; T172A) was transfected into OB-6 cells (Fig. 4D) . As demonstrated in Fig.  4D , transfection with sh-AMPKα1 or dn-AMPKα1 almost completely blocked LV-MALAT1-induced AMPK activation (AMPKα1-ACC phosphorylation) in OB-6 cells. Moreover, LV-MALAT1 treatment was ineffective against Dex-induced injury in OB-6 cells transfected with sh-AMPKα1 or dn-AMPKα1 (Fig. 4E and F) . Therefore, when AMPKα1 was silenced or mutated, LV-MALAT1 failed to inhibit Dex-induced OB-6 cell injuries. These results suggest Fig. 4 . AMPK activation mediates LV-MALAT1-induced osteoblast cytoprotection against Dex-induced injuries. The expression of Ppm1e mRNA (A and G) and listed proteins (B and H), and relative AMPK activity (C and I) were assessed in stable OB-6 cells (A-C) or primary human osteoblasts (G-I) transfected with Lnc-MALAT1-expressing lentivirus (LV-MALAT1) or non-sense control lentivirus (LV-C). Stable OB-6 cells transfected with AMPKα1 shRNA (sh-AMPKα1), dominant negative AMPKα1 (dn-AMPKα1-flag, T172A), or scramble control shRNA (scr shRNA), were infected with LV-MALAT1 for 48 h, and the expression of listed proteins was analyzed (D).Cells were further treated with Dex (1 μM) for 24 h, and cell viability (MTT assay; E) and cell death (trypan blue staining assay; F) were evaluated. Expression of the listed proteins was quantified (B, D, and H). For each assay, n=5. "Ctrl" represents untreated control group. *p<0.05 vs. LV-C cells (A, C, G, and I).
# p<0.05 vs. scr shRNA cells (E and F). Experiments in this figure were repeated three times, and similar results were obtained. Fig. 4G and H) , AMPKα1-ACC phosphorylation (Fig. 4H) , and AMPK activation (Fig. 4I) .
Lnc-MALAT1 inhibits Dex-induced oxidative stress in human osteoblasts
Dex induces ROS production to mediate osteoblast injuries [4, 30, 31] . Studies have shown that AMPK activation can inhibit Dex-induced ROS production [4, 30, 31, 49, 50] . Activated AMPK can increase NADPH content and activity to attenuate oxidative stress [49, 51] . AMPK can also induce activation of Nrf2 signaling [28] [29] [30] , which is a key cellular defense mechanism against oxidative stress [52] [53] [54] . In OB-6 cells, transfection with LV-MALAT1 significantly enhanced the mRNA and protein expression of several key Nrf2-dependent enzymes, including HO1, NOQ1, and GCLC ( Fig. 5A and B) . Nrf2 mRNA level was not significantly altered by LV-MALAT1 transfection in OB-6 cells (Fig. 5A ). Nrf2 protein level was, however, significantly increased (Fig. 5B) . These results indicate that LV-MALAT1 activates Nrf2 signaling in OB-6 cells.
Further studies showed that in LV-MALAT1-expressing OB-6 cells, NADPH activity was enhanced (Fig. 5C ), while Dex-induced increase in ROS production or DCF-DA intensity was attenuated (Fig. 5D) . Additionally, Dex-induced mitochondrial depolarization (JC-1 OD increase) was also attenuated (Fig. 5E ). These results suggest that LV-MALAT1 activates Nrf2 and NADPH signaling, thereby inhibiting Dex-induced oxidative stress. In primary human osteoblasts, transfection with LV-MALAT1 similarly enhanced the mRNA expression of Nrf2-dependent genes (Fig. 5F ) as well as NADPH activity (Fig. 5G) .
Discussion
Prolonged and/or excessive Dex usage can cause secondary osteoporosis [55, 56] or osteonecrosis [57] . Reduced number of osteoblasts, decreased osteoblastogenesis, and increased osteoblast apoptosis were detected in the bones of Dex-administered patients [55, 56] . In the present study, in both osteoblastic cells (OB-6 and hFOB1.19 lines) and primary human osteoblasts, overexpression of Lnc-MALAT1 by LV-MALAT1 inhibited Dex-induced viability reduction, cell death, and apoptosis. Conversely, transfection with Lnc-MALAT1 siRNA aggravated Dex-induced injuries. Lnc-MALAT1 overexpression downregulated Ppm1e expression to activate AMPK signaling. Conversely, transfection with AMPKα1 shRNA or its dominant negative mutation almost abolished Lnc-MALAT1-mediated osteoblast cytoprotection. Thus, Lnc-MALAT1 protects human osteoblasts from Dex-induced injury possibly via activation of Ppm1e-AMPK signaling.
AMPK activation can inhibit ROS production and oxidative injury [27, 51] . AMPK activation is essential for NADPH homeostasis [27, 51] . Activated AMPK phosphorylates ACC to prevent NADPH consumption [27] . Furthermore, fatty-acid oxidation by AMPK promotes NADPH synthesis [27] . Recent studies have proposed another mechanism to explain AMPK-induced antioxidant capacity, which involves activation of Nrf2 signaling. Nrf2 binds tokelch-like ECH-associated protein 1 (Keap1), an adaptor protein, which is responsible for cullin 3-dependent Nrf2 ubiquitination and proteasomal degradation [53, 58, 59] . Activated Nrf2 disassociates with Keap1, which leads to Nrf2 protein accumulation, nuclear translocation, and activation [53, 58, 59] . AMPK is shown to directly phosphorylate Nrf2 (at Ser-550) to increase Nrf2 nuclear translocation and activation [29] . Zimmermann et al. previously reported a signaling crosstalk between AMPK and Nrf2 [28] . Compound 991 and PF-06409577, two well-known AMPK activators, have also been shown to activate Nrf2 signaling [30, 45] .
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In this study, we showed that transfection with LV-MALAT1 increased NADPH activity and the expression of Nrf2-dependent genes, and attenuated Dex-induced ROS production in human osteoblastic cells and primary osteoblasts. Therefore, Lnc-MALAT1 could provoke AMPK-dependent antioxidant mechanisms to protect human osteoblasts from Dex-induced injury [22] .
Conclusion
Our results suggest that Lnc-MALAT1 protects human osteoblasts from Dex-induced injuries possibly via activation of Ppm1e-AMPK signaling.
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